159 related articles for article (PubMed ID: 36210027)
81. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
82. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
Körbling M; Giralt S; Khouri I; Mirza N; Donato M; Anderlini P; Fischer H; Andreeff M; McMannis J; Champlin R
J Clin Apher; 2001; 16(2):82-7. PubMed ID: 11746533
[TBL] [Abstract][Full Text] [Related]
83. [Efficacy and Safety of PEG-rhG-CSF in HSC Mobilization in 71 Normal Healthy Donors for Allogeneic Hematopoietic Stem Cell Transplantation].
Liu F; He GC; Yi H; Li YC; Zhang S; Deng R; Deng Y; Lai SH; Su Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):951-956. PubMed ID: 34105499
[TBL] [Abstract][Full Text] [Related]
84. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.
van der Wall E; Richel DJ; Holtkamp MJ; Slaper-Cortenbach IC; van der Schoot CE; Dalesio O; Nooijen WJ; Schornagel JH; Rodenhuis S
Ann Oncol; 1994 Nov; 5(9):795-802. PubMed ID: 7531486
[TBL] [Abstract][Full Text] [Related]
85. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
86. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Bishop MR; Tarantolo SR; Geller RB; Lynch JC; Bierman PJ; Pavletic ZS; Vose JM; Kruse S; Dix SP; Morris ME; Armitage JO; Kessinger A
Blood; 2000 Jul; 96(1):80-5. PubMed ID: 10891434
[TBL] [Abstract][Full Text] [Related]
87. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism.
Beelen DW; Ottinger HD; Elmaagacli A; Scheulen B; Basu O; Kremens B; Havers W; Grosse-Wilde H; Schaefer UW
Blood; 1997 Dec; 90(12):4725-35. PubMed ID: 9389688
[TBL] [Abstract][Full Text] [Related]
88. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
89. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
[TBL] [Abstract][Full Text] [Related]
90. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
Martin PS; Li S; Nikiforow S; Alyea EP; Antin JH; Armand P; Cutler CS; Ho VT; Kekre N; Koreth J; Luckey CJ; Ritz J; Soiffer RJ
Haematologica; 2016 Apr; 101(4):499-505. PubMed ID: 26768686
[TBL] [Abstract][Full Text] [Related]
91. The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes.
Fabrizio V; Wahlquist A; Hill E; Williams E; Kramer C; Jaroscak J; Duong A; Garrett-Mayer E; Hudspeth M
Pediatr Transplant; 2018 Dec; 22(8):e13287. PubMed ID: 30159974
[TBL] [Abstract][Full Text] [Related]
92. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
[TBL] [Abstract][Full Text] [Related]
93. The role of accessory cells in allogeneic peripheral blood stem cell transplantation.
Tanaka J; Imamura M; Kasai M; Asaka M; Torok-Storb B
Int J Hematol; 1999 Feb; 69(2):70-4. PubMed ID: 10071453
[TBL] [Abstract][Full Text] [Related]
94. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation.
Sun YQ; He GL; Chang YJ; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2015 Oct; 94(10):1699-705. PubMed ID: 26152553
[TBL] [Abstract][Full Text] [Related]
95. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.
Bensinger WI; Weaver CH; Appelbaum FR; Rowley S; Demirer T; Sanders J; Storb R; Buckner CD
Blood; 1995 Mar; 85(6):1655-8. PubMed ID: 7534140
[TBL] [Abstract][Full Text] [Related]
96. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
[TBL] [Abstract][Full Text] [Related]
97. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
98. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
99. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
[TBL] [Abstract][Full Text] [Related]
100. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
